{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.31","value":"20.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"}],"units":"Participants"}],"title":"Mirvetuximab Soravtansine at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.770","value":"22.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"Mirvetuximab Soravtansine at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.463","value":"23.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"}],"units":"Participants"}],"title":"Total M9346A antibody at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.52","value":"31.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"Total M9346A antibody at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"265.7","value":"348.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"}],"units":"Participants"}],"title":"DM4 at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"280.9","value":"347.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"DM4 at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1496","value":"1586"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"}],"units":"Participants"}],"title":"S-methyl DM4 at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1278","value":"1512"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"S-methyl DM4 at Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"}],"units":"Participants"}],"description":"PK parameters were calculated using standard non-compartmental methods.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received mirvetuximab soravtansine at 6 mg/kg AIBW administered IV on Day 1 of a 3 week cycle. Participants continued to receive study drug until they experienced PD per RECIST version 1.1 (as assessed by BIRC), experienced unacceptable toxicity, or withdrew consent, whichever came first, or until the sponsor terminated the study. (Maximum exposure: 86.9 weeks)","id":"OG000","title":"Mirvetuximab Soravtansine"}],"paramType":"MEAN","populationDescription":"PK population included all participants who received at least 1 infusion of mirvetuximab soravtansine, had evaluable PK data, and had samples collected with no major deviations related to administration of study drug. Here, 'number analyzed'=participants evaluable for specified categories.","reportingStatus":"POSTED","timeFrame":"Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1 and 3; and Day 8 and 15 of Cycles 1 and 3","title":"Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-methyl DM4","type":"SECONDARY","unitOfMeasure":"hours*milligrams/milliliter (hr*mg/mL)"}